Pharmacophore-based discovery of inhibitors of a novel drug/proton antiporter in human brain endothelial hCMEC/D3 cell line

British Journal of Pharmacology

Volumn 172, Issue 20, 2015, Pages 4888-4904

  Chapy, Hélène ^a   Goracci, Laura ^b   Vayer, Philippe ^c   Parmentier, Yannick ^c   Carrupt, Pierre Alain ^d   Declèves, Xavier ^a,e   Scherrmann, Jean Michel ^a,e   Cisternino, Salvatore ^a,e   Cruciani, Gabriele ^b  

^a UMR S 1144   (France)

^b UNIVERSITY OF PERUGIA   (Italy)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AE 641 00604022; AE 848 36959133; AG 690 11629084; AI 204 31729011; AJ 292 13998281; AJ 292 41721907; AMITRIPTYLINE; AN 465 43421955; AO 365 42033227; AO 365 42320587; AQ 405 42300085; BUPRENORPHINE; CLONIDINE; COCAINE; CODEINE; DESIPRAMINE; DIPHENHYDRAMINE; HOMOCOCAINE; HYDROCODONE; IMIPRAMINE; METHADONE; MULTIDRUG RESISTANCE PROTEIN 1; NALOXONE; NORCOCAINE; NORTRIPTYLINE; PROTEIN INHIBITOR; PROTON ANTIPORTER INHIBITOR; QUININE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; ANTIPORTER; DRUG RECEPTOR; PROTON;

AREA UNDER THE CURVE; ARTICLE; BRAIN ENDOTHELIAL CELL; CANCER CELL LINE; CEMC D3 CELL LINE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; FALSE POSITIVE RESULT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MATHEMATICAL ANALYSIS; PARTICLE SIZE; PHARMACOPHORE; PRINCIPAL COORDINATE ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SCREENING; SYNTHESIS; ANTAGONISTS AND INHIBITORS; BRAIN; CELL LINE; CYTOLOGY; METABOLISM;

ANTIPORTERS; BRAIN; CELL LINE; CLONIDINE; COCAINE; ENDOTHELIAL CELLS; HUMANS; NALOXONE; PROTONS; RECEPTORS, DRUG;

EID: 84940958945     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13258     Document Type: Article

References (48)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ, (2010). Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13-25.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013). The concise guide to pharmacology 2013/14: transporters. Br J Pharmacol 170: 1706-1796.
3. + antiporter that interacts with addictive drugs. J Cereb Blood Flow Metab 29: 1293-1304.
4. Andre P, Saubamea B, Cochois-Guegan V, Marie-Claire C, Cattelotte J, Smirnova M, et al., (2012). Transport of biogenic amine neurotransmitters at the mouse blood-retina and blood-brain barriers by uptake1 and uptake2. J Cereb Blood Flow Metab 32: 1989-2001.
5. Astorga B, Ekins S, Morales M, Wright SH, (2012). Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther 341: 743-755.
6. Baroni M, Cruciani G, Sciabola S, Perruccio F, Mason JS, (2007). A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model 47: 279-294.
7. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, et al., (2001). Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A 98: 8966-8971.
8. Broccatelli F, Carosati E, Neri A, Frosini M, Goracci L, Oprea TI, et al., (2011). A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 54: 1740-1751.
9. Chapy H, Andre P, Declèves X, Scherrmann JM, Cisternino S, (2015). Polyspecific drug proton-antiporter mediates diphenhydramine and clonidine transport at the mouse blood-retina barrier. Br J Pharmacol. doi: 10.1111/bph.13246.
10. Chapy H, Smirnova M, Andre P, Schlatter J, Chiadmi F, Couraud P, et al., (2014). Carrier-mediated cocaine transport at the blood-brain barrier as a putative mechanism in addiction liability. Int J Neuropsychopharmacol 18. doi: 10.1093/ijnp/pyu001.
11. Cisternino S, Chapy H, Andre P, Smirnova M, Debray M, Scherrmann JM, (2013). Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier. AAPS J 15: 299-307.
12. Crivori P, Cruciani G, Carrupt PA, Testa B, (2000). Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 43: 2204-2216.
13. Cross S, Baroni M, Goracci L, Cruciani G, (2012). GRID-based three-dimensional pharmacophores I: FLAPpharm, a novel approach for pharmacophore elucidation. J Chem Inf Model 52: 2587-2598.
14. Cruciani C, Crivori P, Carrupt PA, Testa B, (2000). Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J Mol Struc-Theochem 503: 17-30.
15. Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA, et al., (2009). Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 77: 897-909.
16. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, et al., (2002). Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61: 964-973.
17. Fischer W, Bernhagen J, Neubert RH, Brandsch M, (2010). Uptake of codeine into intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells. Eur J Pharm Sci 41: 31-42.
18. Fischer W, Metzner L, Hoffmann K, Neubert RH, Brandsch M, (2006). Substrate specificity and mechanism of the intestinal clonidine uptake by Caco-2 cells. Pharm Res 23: 131-137.
19. Giacomini KM, Consortium IT, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al., (2010). Membrane transporters in drug development. Nature Rev Drug Discovery 9: 215-236.
20. Goldberg MJ, Spector R, Chiang CK, (1987). Transport of diphenhydramine in the central nervous system. J Pharmacol Exp Ther 240: 717-722.
21. Goracci L, Buratta S, Urbanelli L, Ferrara G, Di Guida R, Emiliani C, et al., (2014). Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach. Eur J Med Chem 92C: 49-63.
22. Gorelick DA, (2012). Pharmacokinetic strategies for treatment of drug overdose and addiction. Future Med Chem 4: 227-243.
23. Koepsell H, Lips K, Volk C, (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24: 1227-1251.
24. Kuwayama K, Inoue H, Kanamori T, Tsujikawa K, Miyaguchi H, Iwata Y, et al., (2008). Uptake of 3,4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells. Biochim Biophys Acta 1778: 42-50.
25. Law CJ, Maloney PC, Wang DN, (2008). Ins and outs of major facilitator superfamily antiporters. Annu Rev Microbiol 62: 289-305.
26. Madej MG, Dang S, Yan N, Kaback HR, (2013). Evolutionary mix-and-match with MFS transporters. Proc Natl Acad Sci U S A 110: 5870-5874.
27. Mannhold R, Berellini G, Carosati E, Benedetti P, (2006). Use of MIF-based VolSurf descriptors in physicochemical and pharmacokinetic studies. In. Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction, edn, Vol. 27: Wiley-VCH: New York. pp 173-196.
28. Milletti F, Storchi L, Goracci L, Bendels S, Wagner B, Kansy M, et al., (2010). Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series. Eur J Med Chem 45: 4270-4279.
29. Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, et al., (2008). Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 36: 2005-2013.
30. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42: D1098-106.
31. Penzotti JE, Lamb ML, Evensen E, Grootenhuis PD, (2002). A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 45: 1737-1740.
32. + antiporters in chemical stress response in yeast. Trends Microbiol 17: 22-31.
33. Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, et al., (2011). Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. J Pharm Sci 100: 3912-3923.
34. Samaha AN, Mallet N, Ferguson SM, Gonon F, Robinson TE, (2004). The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction. J Neurosci 24: 6362-6370.
35. Samaha AN, Robinson TE, (2005). Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 26: 82-87.
36. Sedykh A, Fourches D, Duan J, Hucke O, Garneau M, Zhu H, et al., (2013). Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res 30: 996-1007.
37. Seelig A, Gottschlich R, Devant RM, (1994). A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc Natl Acad Sci U S A 91: 68-72.
38. Seleman M, Chapy H, Cisternino S, Courtin C, Smirnova M, Schlatter J, et al., (2014). Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties. Psychopharmacology (Berl) 231: 3139-3149.
39. Shaffer CL, Osgood SM, Mancuso JY, Doran AC, (2014). Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. J Pharm Sci 103: 1557-1562.
40. Sirci F, Goracci L, Rodriguez D, van Muijlwijk-Koezen J, Gutierrez-de-Teran H, Mannhold R, (2012). Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A(1), A (2A), A (2B), and A (3) receptor antagonists. J Comput Aided Mol Des 26: 1247-1266.
41. Slavov SH, Wilkes JG, Buzatu DA, Kruhlak NL, Willard JM, Hanig JP, et al., (2014). Computational identification of a phospholipidosis toxicophore using (13)C and (15)N NMR-distance based fingerprints. Bioorg Med Chem 22: 6706-6714.
42. Stone TW, Darlington LG, (2002). Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1: 609-620.
43. Thiele I, Swainston N, Fleming RM, Hoppe A, Sahoo S, Aurich MK, et al., (2013). A community-driven global reconstruction of human metabolism. Nat Biotechnol 31: 419-425.
44. Volkow ND, Wang GJ, Fischman MW, Foltin R, Fowler JS, Franceschi D, et al., (2000). Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci 67: 1507-1515.
45. Volkow ND, Wang GJ, Fowler JS, Tomasi D, (2012). Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 52: 321-336.
46. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al., (2013). HMDB 3.0-the Human Metabolome Database in 2013. Nucleic Acids Res 41: D801-807.
47. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, et al., (2013). Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem 56: 781-795.
48. Xu Y, Liu X, Li S, Zhou N, Gong L, Luo C, et al., (2013). Combinatorial pharmacophore modeling of organic cation transporter 2 (OCT2) inhibitors: insights into multiple inhibitory mechanisms. Mol Pharm 10: 4611-4619.